Abbott
As of the edition of 20 October 2026, Abbott runs 141 drugs, 109 of them marketed; it is on route A at 31 targets and on route B at 5 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 26 company names in this family.
- Kos Pharmaceuticals: acquired in 2006; successor Abbott Laboratories
- Facet Biotech: acquired in 2010; successor Abbott Laboratories
- Inverness Medical Innovations: acquired in 2017; successor Abbott Laboratories
- Replidyne: acquired in 2023; successor Abbott Laboratories
Drugs by status
| Status | Count |
|---|---|
| Marketed | 109 |
| Active | 1 |
| Went quiet | 13 |
| Stopped | 15 |
| Withdrawn from market | 2 |
| Status not established | 1 |
| Total | 141 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Dexmedetomidine | none listed | 9 |
| Bupivacaine | none listed | 1 |
| Lidocaine | none listed | 2 |
| Ritonavir | none listed | 0 |
| Fentanyl | none listed | 6 |
| Ibuprofen | none listed | 11 |
| Oxytocin | none listed | 1 |
| Morphine | none listed | 2 |
| Adalimumab | Ends 2028 (orphan exclusivity) | 4 |
| Sodium chloride | none listed | 0 |
| Sevoflurane | none listed | 12 |
| Valproic acid | none listed | 2 |
| Gabapentin | none listed | 1 |
| Warfarin | none listed | 1 |
| Hydrochlorothiazide | none listed | 4 |
| Metronidazole | none listed | 0 |
| Magnesium sulfate anhydrous | none listed | 0 |
| Clarithromycin | none listed | 0 |
| Testosterone | none listed | 4 |
| Furosemide | none listed | 2 |
| Heparin | none listed | 5 |
| Atropine | none listed | 12 |
| Fenofibrate | none listed | 3 |
| Dextrose | none listed | 0 |
| Niacin | none listed | 0 |
A route B row is one company at one target. 84 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 31 targets, route B at 5 targets.
All 36 rows on route A or B
In the product36 company-target rows on route A or B; 33 are not shown here, and no score is.
See all 36 targets where Abbott needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Urinary and reproductive: 53 trials led
- Immune system: 40 trials led
- Cancer: 34 trials led